|
|
|
Volumn 2, Issue 2, 2000, Pages 142-152
|
|
Ramatroban Bayer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID;
7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID;
7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID;
ANTIGEN;
DOMITROBAN;
METHACHOLINE;
OZAGREL;
PROSTAGLANDIN D2;
RAMATROBAN;
SERATRODAST;
SULOTROBAN;
TERFENADINE;
ASTHMA;
BLEEDING;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG BINDING;
DRUG METABOLISM;
DRUG SYNTHESIS;
HUMAN;
HUMAN EXPERIMENT;
MAJOR CLINICAL STUDY;
NONHUMAN;
NORMAL HUMAN;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
REVIEW;
RHINITIS;
STRUCTURE ACTIVITY RELATION;
THROMBOCYTE AGGREGATION INHIBITION;
THROMBOEMBOLISM;
|
|
EID: 0034101336
PISSN: 14648474
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (1)
|
|
References (144)
|
